Hellman & Friedman Capital Partners X (Parallel), LP

10% owner Hellman & Friedman sold 31,868,237 shares ($1.2B) on 2026-05-28; retains 6,377,698 shares post-transaction.

Hellman & Friedman Capital Partners X (Parallel), LP executed 4 separate sales totaling 31,868,237 shares for $1,164,385,709.40 at $36.54 on 2026-05-28, reducing its stake from 38,245,935 shares to 6,377,698 shares (an -83.3% reduction in holdings). The timing occurs with the stock currently at $35.75, down -29.7% from its 52-week high of $50.88 and down -20.1% over the past 30 days. Reviewing the insider's same-ticker history at MDLN, 4 of 5 prior sells were well-timed at the 90-day mark, suggesting a pattern of selling before price declines; however, the cross-ticker track record shows an average 90-day return of +15.4% following sells, indicating mixed timing accuracy across holdings. The sale's magnitude and the substantial post-transaction retention of 6.38M shares signal a significant portfolio exit rather than full liquidation, occurring as the company reports $7.4B in latest-quarter revenue and $239.0M net income with +11.5% annual growth.

H&F Capital Partners X sold 26.13M MDLN shares for $1.1B at $40.51, reducing 10% stake by 77.1%.

Hellman & Friedman Capital Partners X, a 10% shareholder, executed 4 separate sales totaling 26,131,237 shares for $1,058,524,148.39 at $40.51 on 2026-03-10, reducing its position from 33,913,025 shares to 7,781,788 shares—a 77.1% reduction in holdings. The blended average price of $40.51 compares to a current price of $41.07, with the stock down 17.8% from its 52-week high and down 9.3% over the past 30 days. The filer's cross-ticker track record shows 3 prior sells with an average 30-day return of +55.5%, though this cross-ticker track record provides limited insight into timing patterns at this specific ticker; at MDLN itself, 0 of 0 prior sells were well-timed at the 90-day measurement. The substantial reduction in a major shareholder's stake, combined with recent 30-day price weakness and the stock trading below its 52-week high, merits investor attention to the motivations and any material developments at Medline that may have prompted this significant liquidation.

H&F Capital Partners X sells 6.09M MDLN shares at $28.37, reducing stake by 5.0% to 115.79M shares post-transaction.

Hellman & Friedman Capital Partners X, a 10% owner of Medline Inc., executed 3 separate sales totaling 6,088,371 shares for $172,716,735.04 at a blended average price of $28.37 on 2025-12-18. This reduces the filer's holdings from 121,877,338 shares to 115,788,967 shares, a reduction of 5.0%. The transaction occurred 4 trading days after MDLN's recent listing, and the current market price of $42.18 reflects a 48.5% premium to the transaction price, indicating significant post-transaction price appreciation. The Form 4 flags a derivative-conversion transaction, meaning the Table I shares_after figure does not represent the filer's complete position and derivative holdings remain to be disclosed.